NYMXF 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of August, 2026

Commission File Number: 001-12033

Nymox Pharmaceutical Corporation
(Translation of registrant’s name into English)

Bay & Deveaux Streets, Nassau, The Bahamas

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

In shareholder voting concluded on 26 August, 2026, Nymox (the Company) shareholders voted in favor of the following members of the Board of Directors of the Company: Dr. Paul Averback, Chairman; Dr. David Morse; Dr. Russell Thomson; Dr. Kresimir Pucaj, Robert Lachance. Voters of record on August 4, 2026 were eligible to vote. The voting was closed and locked by the transfer agent (Computershare) on 26 August at 5:00 pm EST. Based on the voting record provided: of 105,040,140 total shares issued and outstanding, 47,885,624 shares (45.59%) were voted; the motion to elect directors received 47,066,029 shares (98.29%) in favor, 0 shares against, and 819,595 shares (1.71%) withheld/abstaining, with no spoiled ballots or non-votes recorded. The motion was carried and the nominees were declared duly elected at the virtual meeting held 2 days after the voting was closed and locked. The transcript from 28 August 2026 is attached in Exhibit 99.1.

EXHIBIT INDEX

Exhibit No.		Description
99.1		Transcript of Special Shareholders Meeting, dated August 28, 2026
2
---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 31, 2026

	NYMOX PHARMACEUTICAL CORPORATION
	By:	/s/ Paul Averback
	Name:	Paul Averback
	Title:	President and Chief Executive Officer
3
---

nymox_ex991.htm

EXHIBIT 99.1

Transcript of Special Shareholders Meeting Aug 28 2026

Transcript of Special Shareholders Meeting held virtually, on 28 August 2026 at 4:30 pm, EST

Dr. Paul Averback:

Good afternoon and welcome — I now call this special meeting of the shareholders of NYMOX to order.

I am Paul Averback CEO/President. And I will act as the chairperson of this meeting. Our counsel Lethea Carey will be responsible to document the minutes.

We have been informed by the Transfer Agent that proper notice of this meeting was given to shareholders and that notice of this special meeting was sent to all shareholders of record in accordance with our corporate bylaws.

We refer to the Proxy circular that was sent to shareholders regarding August 4, 2026 as the Record Date.

And we have determined that there are 47,885,624 shares duly represented by proxy. This represents 45.6% of the voting stock. A quorum is represented, and we may conduct the stated business.

The purpose of today’s special meeting is to consider and report upon the following specific business item:

for the limited purpose set out in the Notice; and with re-confirmation that no other business will be entertained;

The purpose is to report voting results and to fill the vacancies on the Board of Directors and elect the new Board of Directors.

The nominees have been previously identified in the Proxy materials,

And they include:

Dr Russell Thomson

Dr Kresimir Pucaj,

Mr Robert Lachance

Dr David Morse

And myself Dr Paul Averback

As there are no further questions about the sole item on the agenda, I will now proceed to report on the official vote count that has been officially confirmed by the staff team from Computershare headed by Patrick Gauthier and Lesley-Anne Alano in conjunction with Broadridge.

Based on the voting record provided: of 105,040,140 total shares issued and outstanding, 47,885,624 shares (45.59%) were voted; the motion to elect directors received 47,066,029 shares (98.29%) in favor, 0 shares against, and 819,595 shares (1.71%) withheld/abstaining, with no spoiled ballots or non-votes recorded.

As Chairman I hereby declare that the motion is carried and the nominees are duly elected.

1

Transcript of Special Shareholders Meeting Aug 28 2026

I hereby confirm that the Board of Directors of the Company now comprises five (5) directors:

Dr Russell Thomson

Dr Kresimir Pucaj

Mr Robert Lachance

Dr David Morse

Dr Paul Averback

effective as of August 28, 2026

Seconded by Dr. David Morse

As the Chair I reiterate that the Meeting was convened for the sole purpose stated in the Notice and that no further business is before the shareholders.

Adjournment

Motion to adjourn the Meeting. Seconded by Dr David Morse

Chair declared the Meeting adjourned.

2